Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2)

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immunotherapy resistance remains a significant challenge in cancer treatment.
• T cell infiltration into the tumor microenvironment (TME) is crucial for effective immunotherapy.
• Pancreatic adenocarcinoma is notably refractory to immunotherapy, characterized by T cell exclusion from the TME.

Purpose of the Study:

• To identify intrinsic tumor mechanisms that shape the immune TME.
• To uncover novel therapeutic targets for overcoming immunotherapy resistance in pancreatic cancer.

Main Methods:

• Unbiased screening of human pancreatic tumors to identify immune-suppressive factors.
• Genetic deletion of candidate genes (EPHA2, PTGS2) in tumor models.
• Assessment of T cell infiltration and tumor response to immunotherapy.
• Pharmacological inhibition of PTGS2 (cyclooxygenase-2).

Main Results:

• EPHA2 was identified as a tumor-intrinsic driver of immunosuppression and T cell exclusion.
• EphA2 deletion reversed T cell exclusion and enhanced immunotherapy response.
• PTGS2 (cyclooxygenase-2) was found downstream of EPHA2 signaling via TGFβ and associated with poor survival.
• Ptgs2 deletion or pharmacological inhibition of PTGS2 also reversed T cell exclusion and sensitized tumors to immunotherapy.

Conclusions:

• EPHA2-PTGS2 signaling within tumor cells dictates the tumor immune phenotype and promotes immunotherapy resistance.
• Targeting the EPHA2-TGFβ-PTGS2 pathway presents a promising therapeutic strategy for immunotherapy-refractory cancers, particularly pancreatic adenocarcinoma.
• Clinical trials combining pathway inhibitors with immunotherapy are warranted to improve treatment outcomes for resistant cancers.